cGMP FACILITY

Sutro announced that it is deprioritizing additional investment into development of luvelta across all indications. The Company will continue to explore global outlicensing opportunities for luvelta. Further, given Sutro’s significant progress in fully externalizing its cell-free manufacturing to scale, the Company intends to exit its internal GMP manufacturing facility by year-end.

Sutro’s cGMP multi-product manufacturing facility, located in San Carlos, CA, utilizes single use and stainless steel technologies for fermentation, cell-free expression, and purification of Drug Intermediate and Drug Substance. Manufacturing capability and capacity support the production of cGMP clinical materials for Sutro and partnered programs.

XtractCF® and lysate reagents from the Sutro cGMP facility can be shipped globally for the manufacture of proteins at partner sites. Our business partners have successfully audited the facility for cGMP compliance repeatedly since 2016.